Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, March 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Five Prime Therapeutics, Inc. Analyst Notes
On March 18, 2014, Five Prime Therapeutics, Inc. (Five Prime Therapeutics) announced that it intends to release its Q4 2013 and full-year 2013 financial results on March 25, 2014, after the US financial markets close. On the same day, the Company has scheduled a conference call and live audio webcast to discuss the Company's financial results at 5:00 p.m. ET / 2:00 p.m. PT, during which it will also provide a general business update. The full analyst notes on Five Prime Therapeutics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03212014/FPRX/report.pdf
Acceleron Pharma Inc. Analyst Notes
On March 17, 2014, Acceleron Pharma Inc. (Acceleron) announced that its collaboration partner, Celgene, has been scheduled to present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis. The presentation will take place during the National Kidney Foundation 2014 Spring Clinical Meeting to be held on April 22-26, 2014 at the MGM Grand Las Vegas, NV. The data is scheduled to be presented on April 23, 2014 from 6:00-7:30 p.m. PST. The full analyst notes on Acceleron Pharma Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03212014/XLRN/report.pdf
Emergent BioSolutions Inc. Analyst Notes
On March 6, 2014, Emergent BioSolutions, Inc. (Emergent BioSolutions) reported Q4 2013 and full-year 2013 financial results. In Q4 2013, the Company's revenues totaled $98.1 million, up 3.7% YoY, while full-year 2013 total revenues were up 10.9% YoY to $312.7 million. Q4 2013 GAAP net income attributable to Emergent BioSolutions was $15.2 million, or $0.41 per diluted share, compared to $16.1 million, or $0.44 per basic share, in Q4 2012. Full-year 2013 GAAP net income attributable to Emergent BioSolutions was $31.1 million, or $0.85 per diluted share, compared to $23.5 million, or $0.65 per diluted share, in full-year 2012. "Total revenue grew 11%, product sales were up 19% and GAAP net income increased 32%. Our biodefense business continued its strong performance reflected by the increased BioThrax doses shipped and better than expected sales of our newly acquired medical countermeasure RSDL. In addition, we continued to advance our key Biosciences product development programs with the goal of partnering for advanced development. Finally, the Cangene transaction furthered our strategic objective of acquiring additional products or companies that leverage our competencies," said Daniel J. Abdun-Nabi, President and CEO of Emergent BioSolutions. The full analyst notes on Emergent BioSolutions Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03212014/EBS/report.pdf
CONMED Corporation Analyst Notes
On March 14, 2014, CONMED Corporation (CONMED) announced that it has received a notice from Voce Capital Management LLC (Voce) of its intention to nominate James W. Green, Alan L. Kaganov, Joshua H. Levine, Jeffrey M. Nugent, and J. Daniel Plants to stand for election to CONMED's Board of Directors at the 2014 Annual Meeting of Shareholders. In addition, the Company also announced that it is postponing the record date for its 2014 Annual Meeting of Shareholders and expects that the new record date will be announced in the near future. However, CONMED expects the meeting to be rescheduled no later than July 31, 2014. The full analyst notes on CONMED Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03212014/CNMD/report.pdf
ImmunoGen, Inc. Analyst Notes
On March 17, 2014, ImmunoGen, Inc. (ImmunoGen) announced that its scientists are scheduled to present at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 5-9, 2014 in San Diego, CA. The Company's poster presentations are scheduled to be presented from April 6-8, 2014. "The presentations scheduled include the pharmacokinetics modeling work which informed our decision to dose IMGN853 based on adjusted ideal body weight and to assess it dosed weekly," said John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer of ImmunoGen. "They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio." The full analyst notes on ImmunoGen, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03212014/IMGN/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article